The company is already renowned by many as a giant in the segment.

AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...

The cash deal will add an experimental drug for moderate to severe atopic dermatitis, building up AbbVie’s core business.

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...

June 19 (Reuters) - AbbVie is nearing a deal to acquire inflammatory disease drug developer Apogee Therapeutics for about $10.9 billion in cash, the Financial Times reported on Friday, citing people ...

AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a ...

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

Apogee Therapeutics is being acquired by AbbVie for $135.11 per share in cash, capping further upside. Click here to read my ...

Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...